Physician compensation is rising faster in cardiology than any other specialty. Still, considering how demanding the job is, many cardiologists still feel underpaid.
Nearly 700 bottles of a popular ACE inhibitor are being recalled after it failed a Organic Impurities Test. The drug was manufactured in India and then distributed by New Jersey-based Rising Pharma Holdings.
Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis .
Performing TAVR on a patient with bicuspid AS can be challenging. Transcatheter aortic root tricuspidization may represent a new treatment strategy for these patients, according to a new first-in-human trial.
In new Neiman Health Policy Institute research, scientists explored the use of artificial intelligence to aid in diagnosing PE on CTPA, with “AI-informed radiologists" scoring high marks.
The TowerBrook Capital-backed breast imaging provider announced the latest openings on May 11, with new centers in Houston and Doylestown, Pennsylvania.
This leaves only about 18% of docs practicing in physician-owned settings as of Jan. 1, with corporations employing an additional 48,000-plus docs over the past two years.
The largest accrediting and certifying organization in U.S. healthcare announced July 29 it will begin upholding standards that distinguish children from adults.
Considering the often-aggressive nature of interval breast cancer, the findings could represent a significant step toward improving patient outcomes, authors of a new research paper suggest.
Physician compensation is rising faster in cardiology than any other specialty. Still, considering how demanding the job is, many cardiologists still feel underpaid.
Nearly 700 bottles of a popular ACE inhibitor are being recalled after it failed a Organic Impurities Test. The drug was manufactured in India and then distributed by New Jersey-based Rising Pharma Holdings.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
